Local research. Human connections. WCR Miami Lakes (786) 483-7856
Back to study searchNCT07928102
Not yet recruitingNCT07928102ClinicalTrials.gov record

Automated Reporting System for Biliopancreatic Endoscopic Ultrasound

Biliopancreatic Diseases

THE QUICK READ

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type
Observational
Phase
Not applicable / not listed
Age range
Not specified - 18 years
Sex eligible
All sexes
Healthy volunteers
Not accepted
Participants
420 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

This study aims to develop and prospectively validate an automated reporting system to generate structured preliminary biliopancreatic EUS reports using information collected before and during EUS examinations. System development will be completed before prospective validation, and patients included in system development will be separate from those enrolled in prospective validation.

The prospective multicenter validation will enroll 420 adults undergoing EUS for suspected or confirmed biliopancreatic disease. Each patient will contribute only the first eligible EUS examination. The primary endpoint is the difference in clinical acceptance rates between system-generated preliminary reports and independently prepared manual preliminary reports. Non-inferiority will be assessed using a predefined margin.

A nested endosonographer-reporting substudy will also compare completion time and quality between final reports prepared by endosonographers with and without assistance of a system-generated preliminary report. The study will assess the ability of automated reporting to support accurate and efficient EUS reporting while routine clinical care remains unchanged.

Read the full description

This study aims to develop and validate an automated reporting system which will generate structured preliminary reports based on preprocedural clinical data, the endosonographer's speech during EUS, EUS videos, and EUS procedural records. System development will be completed before prospective validation, using a dataset separated from the prospective validation cohort.

The prospective multicenter validation will enroll 420 adults undergoing EUS for suspected or confirmed biliopancreatic diseases. Each patient will contribute only the first eligible EUS examination as the index EUS examination. For each index examination, the automated reporting system will generate a system-generated preliminary report, while the examining endosonographer will independently generate the manual preliminary report without AI assistance. Additionally, speech-only preliminary reports and video-only preliminary reports will be generated to explore the contribution of different data inputs.

Each report will be independently assessed by two EUS experts blinded to the report source. Disagreements between the two assessors will be adjudicated by a third expert. Significant clinical corrections are defined as corrections to errors or omissions that could affect lesion localization, diagnosis, or subsequent clinical management; word and format changes alone do not qualify as significant clinical corrections. Clinical acceptance rate is defined as the proportion of all reports generated for enrolled patients that were accepted without significant clinical corrections. The primary endpoint is the difference in clinical acceptance rates between the system-generated preliminary report and the manual preliminary report of the same patient.

Additionally, a predefined nested endosonographer-reporting substudy will use the same cases to compare completion time and quality between final reports prepared by endosonographers with and without assistance of a system-generated preliminary report. Reporting tasks will be randomly assigned to endosonographers. This substudy will evaluate whether the automated reporting system can improve reporting efficiency while maintaining final report quality.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

1. Patients aged ≥ 18years;
2. Patients undergoing EUS for suspected or confirmed biliopancreatic disease;
3. Patients who voluntarily sign the informed consent.

Exclusion Criteria:

1. Patients who are unable to complete standard scanning due to gastrointestinal obstruction or other reasons;
2. Patients who underwent surgical treatment or anatomical alterations of the pancreas due to lesions in other thoracic and/or abdominal organs, as well as patients with congenital anatomical abnormalities;
3. Patients undergoing EUS primarily for therapeutic purpose such as drainage.

Study population

Adults undergoing EUS for suspected or confirmed biliopancreatic disease at participating hospitals.

Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment
Not reported
Masking
Not reported
Adults undergoing biliopancreatic endoscopic ultrasound

Adults undergoing EUS for suspected or confirmed biliopancreatic diseases will participate in this study. Each patient provides only the first eligible EUS examination for a prospective validation of the automated reporting system.

Device: Automated Reporting System for Biliopancreatic Endoscopic Ultrasound

Automated Reporting System for Biliopancreatic Endoscopic Ultrasound DEVICE

The system that integrates preprocedural clinical data, the endosonographer's speech during EUS, EUS videos, and EUS procedural records to generate a system-generated preliminary report. The system-generated preliminary report is generated for research validation after the routine EUS examination and is compared with the endosonographer's independent manual preliminary report. The system does not determine the patient's clinical care.

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Difference in clinical acceptance rates between system-generated and manual preliminary reports

Time frame: Preliminary reports from the index EUS examination; assessment within 60 days after EUS.

The within-patient paired difference in clinical acceptance rates, calculated as the rate for system-generated preliminary reports minus that for independently written manual preliminary reports. A report is accepted if it requires no significant clinical corrections-corrections to errors or omissions that could affect lesion localization, diagnosis or clinical management. Failed or blank system-generated reports are classified as not accepted. Non-inferiority is established if the lower limit of the two-sided 95% confidence interval is greater than -5 percentage points.

Secondary measures

Completeness of the system-generated preliminary reports

Time frame: Index EUS examination; report assessment within 60 days.

In the prospective paired validation, completeness is the proportion of applicable, reference-confirmed items correctly documented in each system-generated preliminary report. Items cover actual examination extent, organ findings, lesion descriptions, and sampling records.

Number of significant clinical report corrections

Time frame: Index EUS examination; report assessment within 60 days.

In the prospective paired validation, the number of significant clinical corrections required per system-generated preliminary report will be assessed. Reductions and additions relative to the independent manual preliminary report will also be reported.

Reporting time of the system-generated preliminary report

Time frame: During the first automated report-generation task for the index EUS examination, within 30 days after EUS.

In the prospective paired validation, time is measured from submission of all required inputs-including preprocedural clinical data, the endosonographer's speech, EUS videos, and EUS procedure records-to availability of the first system-generated preliminary report. Failed generation will be reported separately.

Reporting time of the manual preliminary report

Time frame: During the routine reporting session immediately after the index EUS examination, up to 60 days

Description: In the prospective paired validation, time is measured from the endosonographer beginning routine report preparation to submission of the independent manual preliminary report, without AI assistance.

Difference in final report completion time with versus without AI assistance

Time frame: During the assigned reporting tasks for each index EUS examination, up to 60 days

In the randomized endosonographer-reporting substudy, the within-case difference in total time to complete a final report is calculated as unassisted time minus assisted time. Total time includes review of source materials, report generation waiting time where applicable, writing, and verification. This outcome will be formally tested only if non-inferiority of the primary outcome is established.

Quality of final reports in the endosonographer-reporting substudy

Time frame: Final reports from the assigned reporting tasks for each index EUS examination; assessment within 60 days after EUS.

In the randomized endosonographer-reporting substudy, the proportion of final reports accepted without significant clinical corrections will be assessed separately for reports completed with and without access to the system-generated preliminary report. Completeness and clinically important errors and omissions will also be reported.

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Qilu Hospital of Shandong UniversityJinan, Shandong, ChinaStatus unknown

Study team and timeline

Lead sponsor
Qilu Hospital of Shandong University
Study start
Nov 1, 2026 Estimated
Primary completion
Jun 30, 2028 Estimated
Study completion
Dec 31, 2028 Estimated
First posted
Nov 10, 2026 Actual
Last updated
Nov 10, 2026 Actual

Official study contacts

Official study title

Development and Prospective Multicenter Validation of an Automated Reporting System for Biliopancreatic Endoscopic Ultrasound

A HUMAN NEXT STEP

Ask Wellness Clinical Research

Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.

Please do not include medical records, diagnoses, medications, insurance numbers or other sensitive details. This form is for general questions, not urgent care.

Sending a question does not enroll you in a trial.

Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.

Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026